{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:12:37Z","timestamp":1792131157236,"version":"4.4.0"},"reference-count":77,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Lodz, Poland","award":["503\/1-002-01\/503-11-001"],"award-info":[{"award-number":["503\/1-002-01\/503-11-001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Chronic pancreatitis (CP) and autoimmune pancreatitis (AIP) are diseases with overlapping features, both requiring complex management strategies. CP is characterized by pancreatic exocrine insufficiency (PEI) and pain, with treatment focused on symptom relief through pancreatic enzyme replacement therapy (PERT), pain control, and lifestyle and nutritional changes. However, the standard therapy does not address the underlying inflammation or fibrosis, which drives disease progression. AIP, on the other hand, presents with obstructive jaundice and fibrosis and is classified into two subtypes: Type 1 (AIP-1), linked to IgG4-related disease, and Type 2 (AIP-2), associated with inflammatory bowel disease. Treatment for AIP typically involves oral steroids. Immunomodulators and rituximab are used for recurrent or refractory cases. Novel therapies targeting the inflammation and fibrotic components of CP are being explored. A multidisciplinary approach is essential to optimize care and improve patients\u2019 outcomes.<\/jats:p>","DOI":"10.3390\/ph18030311","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:46:57Z","timestamp":1740383217000},"page":"311","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment Strategies for Chronic Pancreatitis (CP)"],"prefix":"10.3390","volume":"18","author":[{"given":"Katarzyna","family":"T\u0142ustochowicz","sequence":"first","affiliation":[{"name":"Department of Digestive Tract Diseases, Medical University of Lodz, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Krajewska","sequence":"additional","affiliation":[{"name":"Department of Digestive Tract Diseases, Medical University of Lodz, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianna","family":"Kowalik","sequence":"additional","affiliation":[{"name":"Department of Digestive Tract Diseases, Medical University of Lodz, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1825-1807","authenticated-orcid":false,"given":"Ewa","family":"Ma\u0142ecka-Wojciesko","sequence":"additional","affiliation":[{"name":"Department of Digestive Tract Diseases, Medical University of Lodz, 90-153 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/j.1365-2036.2011.04631.x","article-title":"A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery","volume":"33","author":"Gubergrits","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3904\/kjim.2019.051","article-title":"Recent advances in the diagnosis and management of chronic pancreatitis","volume":"34","author":"Kwon","year":"2019","journal-title":"Korean J. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/S0140-6736(16)00097-0","article-title":"Chronic pancreatitis","volume":"387","author":"Majumder","year":"2016","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e00027","DOI":"10.14309\/ctg.0000000000000027","article-title":"Pancreatitis: TIGAR-O Version 2 Risk\/Etiology Checklist With Topic Reviews, Updates, and Use Primers","volume":"10","author":"Whitcomb","year":"2019","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_5","first-page":"387","article-title":"Alcohol as a Risk Factor for Pancreatitis. A Systematic Review and Meta-Analysis","volume":"10","author":"Irving","year":"2009","journal-title":"Jop"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000499138","article-title":"Etiology and Risk Factors of Acute and Chronic Pancreatitis","volume":"35","author":"Weiss","year":"2019","journal-title":"Visc. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1053\/j.gastro.2014.11.002","article-title":"Alcohol disrupts levels and function of the cystic fibrosis transmembrane conductance regulator to promote development of pancreatitis","volume":"148","author":"Pallagi","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1136\/gut.2005.064808","article-title":"Complete cystic fibrosis transmembrane conductance regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls","volume":"54","author":"Weiss","year":"2005","journal-title":"Gut"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/ng1096-141","article-title":"Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene","volume":"14","author":"Whitcomb","year":"1996","journal-title":"Nat. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0002-9343(01)00958-5","article-title":"Clinical characterization of patients with hereditary pancreatitis and mutations in the cationic trypsinogen gene","volume":"111","author":"Keim","year":"2001","journal-title":"Am. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.pan.2015.05.476","article-title":"Genetic susceptibility factors for alcohol-induced chronic pancreatitis","volume":"15","author":"Aghdassi","year":"2015","journal-title":"Pancreatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11938-007-0036-9","article-title":"Current treatment options for chronic pancreatitis","volume":"10","author":"Aziz","year":"2007","journal-title":"Curr. Treat. Options Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/j.1572-0241.2004.30661.x","article-title":"Fat malabsorption screening in chronic pancreatitis","volume":"99","author":"Dumasy","year":"2004","journal-title":"Am. J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.clnu.2020.01.004","article-title":"ESPEN guideline on clinical nutrition in acute and chronic pancreatitis","volume":"39","author":"Arvanitakis","year":"2020","journal-title":"Clin. Nutr."},{"key":"ref_15","first-page":"1474","article-title":"Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: Systematic review and meta-analysis","volume":"66","author":"Huang","year":"2017","journal-title":"Gut"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/2050640616684695","article-title":"United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU)","volume":"5","author":"Rosendahl","year":"2017","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_17","first-page":"236","article-title":"Global burden of five major types of gastrointestinal cancer","volume":"19","author":"Singh","year":"2024","journal-title":"Prz. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/gut.25.7.756","article-title":"Classification of pancreatitis","volume":"25","author":"Sarner","year":"1984","journal-title":"Gut"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.pan.2019.09.013","article-title":"Computed tomography based scoring system in a prospectively ascertained cohort of patients with chronic pancreatitis","volume":"19","author":"Dasyam","year":"2019","journal-title":"Pancreatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s10620-017-4493-2","article-title":"Diagnosing Chronic Pancreatitis","volume":"62","author":"Anaizi","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pan.2012.11.310","article-title":"The Spanish Pancreatic Club\u2019s recommendations for the diagnosis and treatment of chronic pancreatitis: Part 2 (treatment)","volume":"13","author":"Aparicio","year":"2013","journal-title":"Pancreatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.14309\/ajg.0000000000000535","article-title":"ACG Clinical Guideline: Chronic Pancreatitis","volume":"115","author":"Gardner","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_23","first-page":"241","article-title":"Treatment of Alcoholic Pancreatitis","volume":"23","author":"Schneider","year":"2006","journal-title":"Dig. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrgastro.2010.6","article-title":"The role of alcohol and smoking in pancreatitis","volume":"7","author":"Yadav","year":"2010","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1053\/j.gastro.2015.07.066","article-title":"Frequency of Progression From Acute to Chronic Pancreatitis and Risk Factors: A Meta-analysis","volume":"149","author":"Sankaran","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.cgh.2010.10.015","article-title":"Alcohol and Smoking as Risk Factors in an Epidemiology Study of Patients With Chronic Pancreatitis","volume":"9","author":"Yadav","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/mpa.0b013e31812e965e","article-title":"Smoking cessation at the clinical onset of chronic pancreatitis and risk of pancreatic calcifications","volume":"35","author":"Talamini","year":"2007","journal-title":"Pancreas"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Dominguez-Mu\u00f1oz, J.E., Vujasinovic, M., de la Iglesia, D., Cahen, D., Capurso, G., Gubergrits, N., Hegyi, P., Hungin, P., Ockenga, J., and Paiella, S. (2024). European guidelines for the diagnosis and treatment of pancreatic exocrine insufficiency: UEG, EPC, EDS, ESPEN, ESPGHAN, ESDO, and ESPCG evidence-based recommendations. United Eur. Gastroenterol. J.","DOI":"10.1002\/ueg2.12674"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1365-2036.2005.02390.x","article-title":"Effect of the administration schedule on the therapeutic efficacy of oral pancreatic enzyme supplements in patients with exocrine pancreatic insufficiency: A randomized, three-way crossover study","volume":"21","author":"Figueiras","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1053\/j.gastro.2023.07.007","article-title":"AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review","volume":"165","author":"Whitcomb","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000541326","article-title":"Clinical Efficacy and Safety of Treatments for Exocrine Pancreatic Insufficiency: A Systematic Literature Review","volume":"106","author":"Chu","year":"2024","journal-title":"Digestion"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/01.mpa.0000226884.32957.5e","article-title":"The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: A multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis","volume":"33","author":"Safdi","year":"2006","journal-title":"Pancreas"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/MPA.0b013e3181a85eaf","article-title":"Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: An open-label, single-arm, multicenter study","volume":"38","author":"Colombo","year":"2009","journal-title":"Pancreas"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s12325-010-0085-7","article-title":"CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency","volume":"27","author":"Kuhn","year":"2010","journal-title":"Adv. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Siener, R., Machaka, I., Alteheld, B., Bitterlich, N., and Metzner, C. (2020). Effect of Fat-Soluble Vitamins A, D, E and K on Vitamin Status and Metabolic Profile in Patients with Fat Malabsorption with and without Urolithiasis. Nutrients, 12.","DOI":"10.3390\/nu12103110"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1002\/ncp.11130","article-title":"Fat digestion and absorption: Normal physiology and pathophysiology of malabsorption, including diagnostic testing","volume":"39","author":"Omer","year":"2024","journal-title":"Nutr. Clin. Pract."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00223-013-9726-6","article-title":"Double blind randomized control study of intramuscular vitamin D 3 supplementation in tropical calcific pancreatitis","volume":"93","author":"Reddy","year":"2013","journal-title":"Calcif. Tissue Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cell.2014.08.007","article-title":"Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy","volume":"159","author":"Sherman","year":"2014","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3748\/wjg.v24.i2.170","article-title":"Antifibrogenic effects of vitamin D derivatives on mouse pancreatic stellate cells","volume":"24","author":"Wallbaum","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00535-022-01911-6","article-title":"Evidence-based clinical practice guidelines for chronic pancreatitis 2021","volume":"57","author":"Shimizu","year":"2022","journal-title":"J Gastroenterol"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1053\/j.gastro.2011.04.003","article-title":"Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial","volume":"141","author":"Olesen","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_42","first-page":"20","article-title":"Type 3c: Understanding pancreatogenic diabetes","volume":"35","author":"Vonderau","year":"2022","journal-title":"J. Am. Acad. Physician Assist."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.cgh.2009.07.038","article-title":"Roles of pancreatic stellate cells in pancreatic inflammation and fibrosis","volume":"7","author":"Masamune","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1053\/j.gastro.2012.11.037","article-title":"A starring role for stellate cells in the pancreatic cancer microenvironment","volume":"144","author":"Apte","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Huang, C., Iovanna, J., and Santofimia-Casta\u00f1o, P. (2021). Targeting Fibrosis: The Bridge That Connects Pancreatitis and Pancreatic Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094970"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","article-title":"Hepatic fibrosis: Concept to treatment","volume":"62","author":"Trautwein","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1007\/s10620-019-05863-5","article-title":"Cholecystokinin Receptor Antagonist Therapy Decreases Inflammation and Fibrosis in Chronic Pancreatitis","volume":"65","author":"Nadella","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.pan.2022.05.002","article-title":"Pirfenidone ameliorates chronic pancreatitis in mouse models through immune and cytokine modulation","volume":"22","author":"Bava","year":"2022","journal-title":"Pancreatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"104357","DOI":"10.1016\/j.phrs.2019.104357","article-title":"Dasatinib ameliorates chronic pancreatitis induced by caerulein via anti-fibrotic and anti-inflammatory mechanism","volume":"147","author":"Zeng","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Ciofoaia, V., Chen, W., Tarek, B.W., Gay, M., Shivapurkar, N., and Smith, J.P. (2024). The Role of a Cholecystokinin Receptor Antagonist in the Management of Chronic Pancreatitis: A Phase 1 Trial. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16050611"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pan.2022.12.008","article-title":"The Phase 1\/2 Trial of Indomethacin in Chronic Pancreatitis (The PAIR Trial): Protocol for a Parallel Multi-Center Randomized Controlled Trial","volume":"23","author":"Han","year":"2022","journal-title":"Pancreatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/MPA.0b013e3182142fd2","article-title":"International consensus diagnostic criteria for autoimmune pancreatitis: Guidelines of the International Association of Pancreatology","volume":"40","author":"Shimosegawa","year":"2011","journal-title":"Pancreas"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41575-021-00529-y","article-title":"IgG4-related diseases of the digestive tract","volume":"19","author":"Vujasinovic","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00535-022-01857-9","article-title":"Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2020","volume":"57","author":"Okazaki","year":"2022","journal-title":"J Gastroenterol"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/01.SLA.0000071516.54864.C1","article-title":"Results of pancreaticoduodenectomy for lymphoplasmacytic sclerosing pancreatitis","volume":"237","author":"Hardacre","year":"2003","journal-title":"Ann. Surg."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/art.41052","article-title":"Activated M2 Macrophages Contribute to the Pathogenesis of IgG4-Related Disease via Toll-like Receptor 7\/Interleukin-33 Signaling","volume":"72","author":"Ishiguro","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nri3865","article-title":"The multifaceted biology of plasmacytoid dendritic cells","volume":"15","author":"Swiecki","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3748\/wjg.v30.i8.817","article-title":"Autoimmune pancreatitis: Cornerstones and future perspectives","volume":"30","author":"Gallo","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00261-019-02275-x","article-title":"Autoimmune pancreatitis: An update","volume":"45","author":"Khandelwal","year":"2020","journal-title":"Abdom. Radiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MOG.0000000000000655","article-title":"Autoimmune pancreatitis type 2","volume":"36","author":"Frulloni","year":"2020","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/gutjnl-2012-303617","article-title":"Long-term outcomes of autoimmune pancreatitis: A multicentre, international analysis","volume":"62","author":"Hart","year":"2012","journal-title":"Gut"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/MPA.0b013e3182258a15","article-title":"Clinical profile of autoimmune pancreatitis and its histological subtypes: An international multicenter survey","volume":"40","author":"Kamisawa","year":"2011","journal-title":"Pancreas"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00428-015-1850-4","article-title":"Potential role of Th17 cells in the pathogenesis of type 2 autoimmune pancreatitis","volume":"467","author":"Loos","year":"2015","journal-title":"Virchows Arch."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5114\/ceji.2014.42129","article-title":"Multiple gene mutations in patients with type 2 autoimmune pancreatitis and its clinical features","volume":"39","author":"Dong","year":"2014","journal-title":"Cent. Eur. J. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pan.2016.12.003","article-title":"International consensus for the treatment of autoimmune pancreatitis","volume":"17","author":"Okazaki","year":"2017","journal-title":"Pancreatology"},{"key":"ref_66","first-page":"80","article-title":"European Guideline on IgG4-related digestive disease\u2014UEG and SGF evidence-based recommendations","volume":"8","author":"Beuers","year":"2020","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Nista, E.C., De Lucia, S.S., Manilla, V., Schepis, T., Pellegrino, A., Ojetti, V., Pignataro, G., Verme, L.Z.D., Franceschi, F., and Gasbarrini, A. (2022). Autoimmune Pancreatitis: From Pathogenesis to Treatment. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012667"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.dld.2013.06.006","article-title":"Determination of steroid response by abdominal ultrasound in cases with autoimmune pancreatitis","volume":"45","author":"Matsubayashi","year":"2013","journal-title":"Dig. Liver Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.pan.2021.05.303","article-title":"Determination of the duration of glucocorticoid therapy in type 1 autoimmune pancreatitis: A systematic review and meta-analysis","volume":"21","author":"Yoon","year":"2021","journal-title":"Pancreatology"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Strig\u00e1\u010d, A., Caban, M., Ma\u0142ecka-Wojciesko, E., and Talar-Wojnarowska, R. (2024). Safety and Effectiveness of Thiopurines and Small Molecules in Elderly Patients with Inflammatory Bowel Diseases. J. Clin. Med., 13.","DOI":"10.3390\/jcm13164678"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e4002","DOI":"10.1097\/MD.0000000000004002","article-title":"Therapeutic approach to IgG4-related disease: A systematic review","volume":"95","author":"Kostov","year":"2016","journal-title":"Medicine"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Minaga, K., Watanabe, T., Hara, A., Yoshikawa, T., Kamata, K., and Kudo, M. (2021). Plasmacytoid Dendritic Cells as a New Therapeutic Target for Autoimmune Pancreatitis and IgG4-Related Disease. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.713779"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"113673","DOI":"10.1016\/j.intimp.2024.113673","article-title":"Neutrophil extracellular DNA traps activate the TLR9 signaling pathway of pancreatic ductal epithelial cells in patients with type 2 autoimmune pancreatitis","volume":"144","author":"Li","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40266-018-0534-6","article-title":"IgG4-Related Disease: Beyond Glucocorticoids","volume":"35","author":"Akiyama","year":"2018","journal-title":"Drugs Aging"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1136\/gutjnl-2012-302886","article-title":"Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: The Mayo Clinic experience","volume":"62","author":"Hart","year":"2013","journal-title":"Gut"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.14309\/ajg.0000000000000668","article-title":"Antitumor Necrosis Factor Therapy Is Effective for Autoimmune Pancreatitis Type 2","volume":"115","author":"Lorenzo","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/ecco-jcc\/jjad072","article-title":"Ustekinumab as Induction and Maintenance Therapy in Patients with Inflammatory Bowel Disease and Type II Autoimmune Pancreatitis: Report of Two Cases","volume":"17","author":"Lauri","year":"2023","journal-title":"J. Crohns Colitis"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/3\/311\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:41:15Z","timestamp":1760028075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/3\/311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":77,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["ph18030311"],"URL":"https:\/\/doi.org\/10.3390\/ph18030311","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]}}}